Change at the top for Regenxbio
US gene therapy company Regenxbio (Nasdaq: RGNX) has announced that co-founder Kenneth Mills is to step down as president and chief executive following 15 years of leadership at the company.
Mr Mills, who is taking on an expanded role on the board as chairman, will be replaced as president and chief executive by Curran Simpson, Regenxbio’s current chief operating officer.
Meanwhile, board member Daniel Tassé has been appointed as Regenxbio's lead independent director, a role previously held by Jerry Karabelas. Dr Karabelas and co-founder Allan Fox, who has served as chairman since 2020, will remain on the board.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze